Bagsværd, Denmark, 29 October 2020 – On 6 August 2020, Novo Nordisk initiated a share repurchase programme in accordance with Article 5 of Regulation No 596/2014 of the European Parliament and Council of 16 April 2014 (MAR) and the Commission Delegated Regulation (EU) 2016/1052 of 8 March 2016 (the "Safe Harbour Rules"). This programme is part of the overall share repurchase programme of up to DKK 17 billion to be executed during a 12-month period beginning 5 February 2020.
Under the programme initiated 6 August 2020, Novo Nordisk has repurchased B shares for an amount up to DKK 2.8 billion in the period from 6 August 2020 to 28 October 2020. The programme is now concluded.
Since the announcement as of 26 October 2020, the following transactions have been made:
| Number of B shares | Average purchase price | Transaction value, DKK | |
| Accumulated, last announcement | 6,199,491 | 2,662,819,274 | |
| 26 October 2020 | 100,000 | 442.84 | 44,284,016 |
| 27 October 2020 | 110,000 | 437.99 | 48,178,667 |
| 28 October 2020 | 104,352 | 428.53 | 44,717,906 |
| Accumulated under the programme | 6,513,843 | 2,799,999,863 |
The details for each transaction made under the share repurchase programme are published on novonordisk.com.
With the transactions stated above, Novo Nordisk owns a total of 26,561,746 B shares of DKK 0.20 as treasury shares, corresponding to 1.1% of the share capital. The total amount of A and B shares in the company is 2,350,000,000 including treasury shares.
Novo Nordisk expects to repurchase B shares for an amount up to DKK 17 billion during a 12-month period beginning 5 February 2020. As of 28 October 2020, Novo Nordisk has since 5 February 2020 repurchased a total of 26,573,022 B shares at an average share price of DKK 427.15 per B share equal to a transaction value of DKK 11,350,787,595.
Novo Nordisk is a leading global healthcare company, founded in 1923 and headquartered in Denmark. Our purpose is to drive change to defeat diabetes and other serious chronic diseases such as obesity and rare blood and endocrine disorders. We do so by pioneering scientific breakthroughs, expanding access to our medicines and working to prevent and ultimately cure disease. Novo Nordisk employs about 43,100 people in 80 countries and markets its products in around 170 countries. Novo Nordisk's B shares are listed on Nasdaq Copenhagen (Novo-B). Its ADRs are listed on the New York Stock Exchange (NVO). For more information, visit novonordisk.com, Facebook, Twitter, LinkedIn, YouTube.
Further information
| Media: | ||
| Anne Margrethe Hauge | +45 4442 3450 | amhg@novonordisk.com |
| Ken Inchausti (US) | +1 609 240 9429 | kiau@novonordisk.com |
| Investors: | ||
| Daniel Muusmann Bohsen | +45 3075 2175 | dabo@novonordisk.com |
| Valdemar Borum Svarrer | +45 3079 0301 | jvls@novonordisk.com |
| Ann Søndermølle Rendbæk | +45 3075 2253 | arnd@novonordisk.com |
| Mark Joseph Root | +45 3079 4211 | mjhr@novonordisk.com |
| Kristoffer Due Berg (US) | +1 609 235 2989 | krdb@novonordisk.com |
Company announcement No 62 / 2020
Attachment
